BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease (AD) trial...Read more
BRAINTREE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully reached the midpoint of the ACCESS-PVI pivotal human clinical trial, enrolling...Read more
BASKING RIDGE, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced...Read more
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 Kisqali® (ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone;...Read more
MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the indication for current-generation INGEVITY™+ Pacing Leads – thin wires placed inside the heart and connected to an implantable...Read more
Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA’s requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoint(s) BridgeBio will...Read more
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Galmed Pharmaceuticals | 14.00 361.76 | $17.87 |
| ZIVO Bioscience | 11.90 1,081.82 | $13.00 |
| Finch Therapeutics | 9.70 538.89 | $11.50 |
| Purple Biotech | 6.68 1,665.59 | $7.08 |
| Ascendis Pharma | 6.18 4.43 | $145.75 |
| TransMedics | 4.61 3.05 | $155.82 |
| ANI Pharmaceuticals | 4.08 7.26 | $60.28 |
| Rhythm Pharmaceuticals | 3.90 7.88 | $53.42 |
| Bio-Rad Laboratories | 3.84 1.16 | $334.10 |
| Cassava Sciences | 3.48 12.28 | $31.82 |
| Singular Genomics | 3.35 26.15 | $16.16 |
| Veradigm | 2.94 43.17 | $9.75 |
| Alnylam Pharmaceuticals | 2.89 1.07 | $273.26 |
| Moderna | 2.82 4.08 | $71.99 |
| Charles River Laboratories | 2.79 1.37 | $206.52 |
| Rocket Pharmaceuticals | 2.48 12.92 | $21.68 |
| Vaxcyte | 2.46 2.15 | $116.70 |
| SIGA Technologies | 2.40 44.12 | $7.84 |
| Company | Volume | Last Trade |
|---|---|---|
| Galmed Pharmaceuticals | 96,077,383 | $17.87 |
| Senseonics | 41,616,960 | $0.44 |
| Vyome | 36,361,564 | $0.22 |
| Immuneering | 35,973,876 | $2.83 |
| Healthcare Triangle | 24,237,753 | $0.45 |
| Talkspace | 20,714,273 | $2.17 |
| Pfizer | 17,345,583 | $29.75 |
| Walgreens Boots Alliance | 12,815,161 | $9.11 |
| bluebird bio | 11,881,399 | $0.50 |
| Allarity Therapeutics | 11,115,575 | $3.00 |
| Hoth Therapeutics | 10,732,643 | $1.07 |
| Tonix Pharmaceuticals | 10,257,071 | $0.15 |
| Summit Therapeutics | 9,823,457 | $26.20 |
| Teladoc Health | 9,490,030 | $9.12 |
| Edwards Lifesciences | 9,358,406 | $67.33 |
| Geron | 8,732,542 | $4.60 |
| Zentalis Pharmaceuticals | 7,267,925 | $4.10 |
| PacBio | 7,220,284 | $1.92 |
| Teva Pharmaceutical | 7,046,012 | $17.87 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
